biotech
Academic and Community Cancer Research United
Sponsor view across the ADC target screen, including linked targets and source-linked trial evidence.
ADC target activity
Tracked targets
| Target | Trial count | Evidence |
|---|---|---|
| HER2 / ERBB2 | 2 | Source |
Linked trials
Clinical evidence links
- NCT04351230: T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (WITHDRAWN)
- NCT04197687: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery (UNKNOWN)